SINGAPORE HEALTH SERVICES PTE LTD
National Cancer Centre of Singapore General Singapore has been awarded a contract to provide tumor types to the NCI for The Cancer Genome Atlas project. Specifically this award is to fund the provision of the cases with tissues and matched normal bloods. These cases are all primary tumor. The collection of the specimens is being performed according to standard protocols, developed by NCI, and consistent with NCI guidelines for Best Practices for biorepositories. The primary goal has been to ensure highest quality of the samples, with minimal warm ischemic time. Tracking of warm ischemic time is performed. Frozen sections are cut from the sample being prepared for TCGA. This frozen section is evaluated by a board certified pathologist with sub-sepcialty expertise in the specific tumor type being assessed. The assessment serves as a mechanism to ascertain cellular composition. If the specimen fails TCGA QA, the project coordinator of NCI will request to retrieve additional specimens from that particular case or consider that case to have failed internal QA. These frozen section slides are then sent with the sample to an NCI core laboratory where pathology metrics are confirmed and molecular analytes extracted. The original de-identified pathology report is available for each submitted case. Clinical data annotation is available for every submitted case that is being offered as part of TCGA. The data annotation proposed is retrospective.